Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Today's Research on CELG, ARNA, INCY, SPPI, and GERN

INCY
Today’s Research on CELG, ARNA, INCY, SPPI, and GERN

StockCall.com Provides Stock Research on Celgene Corp., Arena Pharmaceuticals Inc., Incyte Corp., Spectrum Pharmaceuticals Inc., and Geron Corp.

New York City, New York -- (May 21, 2013)

The biotechnology industry is facing significant challenges due to increasing competition from generic drug makers. With patents on several blockbuster drugs set to expire over the next few years, the competition from generic drug makers is expected to rise further. Another challenge for biotechnology companies is operating in emerging markets. While healthcare spending in many emerging markets is rising, most of these countries do not have proper laws to protect intellectual property rights. Biotech stocks ended mostly lower on Monday as the broad market struggled. Among the major movers were Celgene Corporation (NASDAQ: CELG), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Incyte Corporation (NASDAQ: INCY), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), and Geron Corporation (NASDAQ: GERN). StockCall professionals have completed their technical analysis on CELG, ARNA, INCY, SPPI, and GERN and these free reports are accessible by registering at

www.stockcall.com/research

Shares of Celgene Corporation fell sharply in trading on Monday, extending their losses from previous trading sessions. The stock closed 1.43% lower at $123.12 on volume of 2.24 million after trading between $122.55 and $125.17. Celgene’s shares have now fallen more than 5% in the last three sessions. Despite the recent losses, the company’s shares have gained 56.90% so far in 2013, outperforming the S&P 500. The stock is currently trading 6.60% below its 52-week high. Sign up for the free technical research on CELG at

www.StockCall.com/CELG052113.pdf

Shares of Arena Pharmaceuticals Inc. edged lower in yesterday’s trading session, however, the losses were limited. The stock closed 0.25% lower at $7.96 on volume of 2.88 million. Arena’s shares have traded sideways over the past one month, struggling to break through $8.50 resistance level. The stock is currently trading below its 50-day and 200-day moving averages which is a bearish signal. Be sure to read our latest technical research on ARNA by registering at

www.StockCall.com/ARNA052113.pdf

Shares of Incyte Corporation edged higher on Monday, reversing some of the losses from the previous sessions. The stock closed 0.48% higher at $23.15 on above average volume of 1.27 million. Despite the gains yesterday, Incyte’s shares have fallen more than 2.80% in the last three sessions. The stock, however, is still trading above its 50-day and 200-day moving averages which is a bullish signal. Year-to-date, the company’s shares have gained more than 39.30%, outperforming the S&P 500. Sign up and read the complimentary report on INCY at

www.StockCall.com/INCY052113.pdf

Another major loser in the biotechnology sector yesterday was Spectrum Pharmaceuticals Inc. Shares of the Henderson, Nevada-based company ended 1.09% lower at $8.05 on volume of 675,308. Despite the losses on Monday, Spectrum’s shares have gained 1% in the last three trading sessions. Year-to-date, however, the stock has fallen more than 28%. Shares of SPPI recently crossed above their 50-day moving average which suggests that market sentiment has turned bullish on the stock. The free report on SPPI can be downloaded by signing up now at

www.StockCall.com/SPPI052113.pdf

Shares of Geron Corporation finished flat in Monday’s trading session. The stock closed at $1.12 on volume of 384,320. Geron’s shares have fallen nearly 5.50% in the last three sessions. The stock recently slipped below its 50-day moving average which is a bearish signal. The negative trend is further confirmed by the stock’s MACD chart. Free report on GERN can be accessed by registering at

www.StockCall.com/GERN052113.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

www.stockcall.com

Contact Person:

William T. Knight

Email: info@stockcall.com

Contact Number: (646) 396-9857 (9:00 am EST – 01:30 pm EST)